



Second Patient Cured of HIV and The Implications for American Gene Technologies's AGT103-T

ROCKVILLE, MD, UNITED STATES, March 8, 2019 /EINPresswire.com/ -- American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London--recently reported in the [Wall Street Journal](#) and New York Times. The patient was treated with a bone marrow transplant from a CCR5-Δ32 donor. The London Patient remains HIV negative after receiving no antiretroviral therapy for 18 months. The success of utilizing a CCR5-Δ32 donor for both the Berlin (2007) and London (2019) patients provides evidence that a CCR-5 based gene therapy developed by American Gene Technologies could cure any person infected with HIV.

This news supports AGT's research and development of an HIV cure in the form of a gene therapy product that replicates the effects of the CCR-5 mutation to reconstitute the immune response against HIV, by reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy, similar to the cured "London patient." AGT's HIV gene therapy, [AGT103-T](#), is currently in the late stages of Investigational New Drug (IND) enabling, on track for an application submission this year to the U.S. Food and Drug Administration (FDA).

If AGT receives FDA approval for its IND submission to begin a Phase 1 clinical trial, it will begin infusing patients with AGT103-T. In preparation for its submission, final tests are being performed on AGT103-T as part of a [non-IND clinical trial](#) in which blood is collected from HIV infected study participants via leukapheresis and ran through an 11-day cell process. The cell process product AGT103-T demonstrates the ability to clear itself of HIV when challenged with the virus and by HIV infected human blood.

About American Gene Technologies (AGT)

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, infectious disease, immuno-oncology, and monogenic disorders. AGT forecasts taking its patented candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Five key patents in AGT's novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

Website - <https://www.americangene.com>

LinkedIn - <https://www.linkedin.com/company/american-gene-technologies-international-inc/>

Twitter - <https://twitter.com/americangene>

Facebook - <https://www.facebook.com/amerigene/>

Instagram - <https://www.instagram.com/americangetechnologies/>

American Gene Technologies Contacts:

C. Neil Lyons, Chief Financial Officer

Phone: (301) 337-2269
Email: info@americangene.com

Sasha Whitaker, Digital Marketing and Communications
American Gene Technologies
+1 301-337-2100
[email us here](#)

Visit us on social media:
[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.